IN2013MU02719AIN2719MU2013AIN2013MU02719AIN 2013MU02719 AIN2013MU02719 AIN 2013MU02719AIN 2719MU2013 AIN2719MU2013 AIN 2719MU2013AIN 2013MU02719 AIN2013MU02719 AIN 2013MU02719A
Authority
IN
India
Prior art keywords
compound
formula
hsd1
preparation
disorders
Prior art date
Application number
Inventor
Suneelmanoharbabu; Chennamsetty
Ravishankar; Bokka
Selvam; Paramasivan
Sivaramakrishnan; Hariharan
Yogesh; Hulawale
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr LtdfiledCriticalPiramal Entpr Ltd
Priority to IN2719MU2013priorityCriticalpatent/IN2013MU02719A/en
Publication of IN2013MU02719ApublicationCriticalpatent/IN2013MU02719A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Hydrogenated Pyridines
(AREA)
Abstract
The present invention relates to an improved process for the preparation of the compound (R)-3-((3,5-dichloro-4’-(4-(trifluoromethyl)piperidine-1-carbonyl)-[1,1’-biphenyl]-4-yl)methyl)-1-(4-hydroxypiperidin-1-yl)pyrrolidin-2-onem (compound of formula (I)), which is an inhibitor of 11ß-hydroxysteroid dehydrogenase type 1 enzyme (11- ß-HSD1). The compound of formula (I) is useful in the treatment of diseases or disorders mediated by the modulation of 11-ß-HSD1, such as cognitive disorders and metabolic disorders. The present invention also relates to a process for the preparation of the pharmaceutically acceptable salts of the compound of formula (I).
Process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid and its crystalline form for use as pharmaceutically active compound